CELLWAND COMMUNICATIONS, INC. – Trademark Portfolio
Entity Type: 03
CELLWAND COMMUNICATIONS, INC. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 39 (Transportation & Storage) — 5 filings in this category. The portfolio also extends into Class 36 (Insurance & Financial) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include #TAXI. The owner is based in Toronto, Ontario.
48 Yonge Street, Suite 1200
Toronto, Ontario M5E1G6 , CA
Showing of trademarks Trademarks
Trademark Classifications
CELLWAND COMMUNICATIONS, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does CELLWAND COMMUNICATIONS, INC. have?
CELLWAND COMMUNICATIONS, INC. has 9 U.S. trademarks filed with the USPTO. Of these, 1 registered, 7 abandoned, 1 cancelled.
What trademark classes does CELLWAND COMMUNICATIONS, INC. file in?
CELLWAND COMMUNICATIONS, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 39 (Transportation & Storage), Class 36 (Insurance & Financial), Class 38 (Telecommunications), Class 9 (Computers & Electronics). Class 39 covers transport; packaging and storage of goods; travel arrangement.
What are CELLWAND COMMUNICATIONS, INC.'s most well-known trademarks?
CELLWAND COMMUNICATIONS, INC.'s registered trademark portfolio includes well-known marks such as #TAXI. These are among 1 currently registered trademark in the portfolio.
What is CELLWAND COMMUNICATIONS, INC.'s trademark registration success rate?
CELLWAND COMMUNICATIONS, INC. has a 11% trademark registration rate, with 1 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.